IPI3Kγ has emerged as an unexpected cancer-cell-intrinsic dependency in acute leukemia, with leukemia cells relying on noncanonical PI3Kγ signaling for survival and growth beyond its traditional functions in immune cells. Selectively inhibiting the PI3Kγ complex could therefore expose a therapeutically actionable vulnerability and provide a new targeted treatment strategy for subsets of acute leukemia.